Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Int J Clin Oncol. 2018 Jun;23(3):504-513. doi: 10.1007/s10147-018-1238-y. Epub 2018 Jan 11.
The field of immunotherapy has recently focused on cancers with microsatellite instability (MSI). These cancers include both Lynch-syndrome-associated tumors, which are caused by mismatch repair (MMR) germline mutations, and sporadic MSI tumors, which are mainly attributed to MLH1 promoter methylation. The present study aimed to clarify differences in the histological and PD-L1 expression profiles between these two types of MSI cancers in Japanese patients.
Among 908 cases of colorectal cancer treated via surgical resection from 2008 to 2014, we identified 64 MSI cancers, including 36 sporadic MSI and 28 Lynch-syndrome-associated cancers, using a BRAF V600E mutation analysis and MLH1 methylation analysis. Of the latter subgroup, 21 (75%) harbored MMR germline mutations.
The following were more frequent with sporadic MSI than with Lynch syndrome associated cancers: poor differentiation (50.0 vs. 7.1%, P = 0.0002), especially solid type (30.6 vs. 3.6%, P = 0.0061); medullary morphology (19.4 and 0%, P = 0.015), Crohn-like lymphoid reaction (50.0 vs. 25.0%, P = 0.042), and PD-L1 expression (25.0 vs. 3.6%, P = 0.034). However, the groups did not differ in terms of the mean invasive front and intratumoral CD8-positive cell densities. In a logistic regression analysis, PD-L1 expression correlated with poor differentiation (odds ratio: 7.65, 95% confidence interval: 1.55-37.7, P = 0.012), but not with the difference between sporadic MSI cancer and Lynch-syndrome-associated cancer (odds ratio: 4.74, 95% confidence interval: 0.50-45.0, P = 0.176).
Therefore, compared with Lynch-syndrome-associated cancers, sporadic MSI cancers are more frequently solid, poorly differentiated medullary cancers that express PD-L1.
免疫疗法领域最近专注于具有微卫星不稳定性(MSI)的癌症。这些癌症包括由错配修复(MMR)种系突变引起的林奇综合征相关肿瘤,以及主要归因于 MLH1 启动子甲基化的散发性 MSI 肿瘤。本研究旨在阐明日本患者中这两种 MSI 癌症在组织学和 PD-L1 表达谱方面的差异。
在 2008 年至 2014 年间通过手术切除治疗的 908 例结直肠癌病例中,我们使用 BRAF V600E 突变分析和 MLH1 甲基化分析鉴定了 64 例 MSI 癌症,包括 36 例散发性 MSI 和 28 例林奇综合征相关癌症。在后一组亚组中,21 例(75%)存在 MMR 种系突变。
与林奇综合征相关癌症相比,散发性 MSI 更常见以下特征:分化不良(50.0% vs. 7.1%,P=0.0002),特别是实体型(30.6% vs. 3.6%,P=0.0061);髓样形态(19.4% 和 0%,P=0.015)、克罗恩样淋巴反应(50.0% vs. 25.0%,P=0.042)和 PD-L1 表达(25.0% vs. 3.6%,P=0.034)。然而,两组在侵袭前缘和肿瘤内 CD8 阳性细胞密度方面没有差异。在逻辑回归分析中,PD-L1 表达与分化不良相关(优势比:7.65,95%置信区间:1.55-37.7,P=0.012),但与散发性 MSI 癌症与林奇综合征相关癌症之间的差异无关(优势比:4.74,95%置信区间:0.50-45.0,P=0.176)。
因此,与林奇综合征相关癌症相比,散发性 MSI 癌症更常为表达 PD-L1 的实性、分化不良的髓样癌。